BioCryst Pharmaceuticals, Inc. is a pharmaceutical company headquartered in Birmingham, Alabama.[3] The company focuses on cancer, autoimmune diseases, and viral infections.[3] The company's most notable function has been the production of the antiviral medication Peramivir, which was approved by the FDA for emergency use in the treatment of drug resistant influenza A virus subtype H1N1.[4]
 |
|
| Type | Public (NASDAQ: BCRX) |
|---|---|
| Industry | Healthcare |
| Founded | 1986 |
| Headquarters | Birmingham, Alabama, USA |
| Key people | Jon P. Stonehouse , President and Chief Executive Officer Stuart Grant, Chief Financial Officer |
| Products | Biotechnology |
| Revenue |  US$16.7M (FY 2010)[1] |
| Operating income |  US$-10.3M (FY 2010)[1] |
| Net income | US$-10.2M (FY 2010)[1] |
| Total assets | US$109M (FY 2010)[2] |
| Total equity | US$65.5M (FY 2010)[2] |
| Employees | 80 (2008) |
| Website | www.biocryst.com |
BioCryst Pharmaceuticals, Inc. is a pharmaceutical company headquartered in Birmingham, Alabama.[3] The company focuses on cancer, autoimmune diseases, and viral infections.[3] The company's most notable function has been the production of the antiviral medication Peramivir, which was approved by the FDA for emergency use in the treatment of drug resistant influenza A virus subtype H1N1.[4]
Contents |
History[edit]
The company was founded in 1986 by Charles E. Bugg, Ph.D. and John A. Montgomery, Ph.D. In March 1994, BioCryst became a public company when it completed an Initial Public Offering by listing its shares on the NASDAQ stock exchange. In 2008 the company was named one of the fastest growing companies by Deloitte & Touche in its 2008 list of Technology Fast 500.[5]
In October 2010, BioCryst announced its headquarters would move to Durham, North Carolina, where the company has had an office since 2006.[6]
Pipeline[edit]
- Forodesine HCl, investigational purine nucleoside phosphorylase (PNP) inhibitor for the treatment of T- and B-cell mediated disorders.
- BCX-4208/R3421, a second generation purine nucleoside phosphorylase inhibitor with applications in autoimmune diseases.
- Peramivir is an experimental antiviral drug being developed for the treatment of influenza.
References[edit]
- ^ a b c BioCryst Pharmaceuticals (BCRX) annual SEC income statement filing via Wikinvest.
- ^ a b BioCryst Pharmaceuticals (BCRX) annual SEC balance sheet filing via Wikinvest.
- ^ a b "BioCryst Pharmaceuticals". BioCryst Pharmaceuticals. Retrieved April 29, 2009.
- ^ "Emergency use authorization for the unapproved drug Peramivir". U.S. Centers for Disease Control and Prevention. Retrieved October 28, 2009.[dead link]
- ^ BioCryst named 29th fastest growing tech firm Birmingham Business Journal, November 26, 2008
- ^ Ranii, David (2010-10-14). "BioCryst moving HQ to Durham". News & Observer. Retrieved 2010-10-14.
